Cowen restated their buy rating on shares of Amicus Therapeutics (NASDAQ:FOLD) in a report issued on Thursday morning, AnalystRatings.com reports. They currently have a $31.00 target price on the biopharmaceutical company’s stock.
Other equities research analysts have also recently issued reports about the stock. Janney Montgomery Scott initiated coverage on shares of Amicus Therapeutics in a research report on Friday, April 5th. They set a buy rating and a $13.91 price target on the stock. Cantor Fitzgerald reissued an overweight rating and set a $19.00 price target (down from $20.00) on shares of Amicus Therapeutics in a research report on Wednesday, June 5th. Zacks Investment Research raised shares of Amicus Therapeutics from a sell rating to a hold rating in a research report on Friday, May 3rd. HC Wainwright reissued a buy rating and set a $18.00 price target on shares of Amicus Therapeutics in a research report on Thursday. Finally, BidaskClub raised shares of Amicus Therapeutics from a sell rating to a hold rating in a research report on Friday, June 7th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus target price of $18.06.
NASDAQ:FOLD traded down $0.24 on Thursday, hitting $11.41. 78,705 shares of the company’s stock were exchanged, compared to its average volume of 3,340,796. The business has a 50-day simple moving average of $12.35. The company has a debt-to-equity ratio of 0.45, a quick ratio of 7.21 and a current ratio of 7.33. Amicus Therapeutics has a 52 week low of $8.27 and a 52 week high of $15.85. The stock has a market capitalization of $2.68 billion, a P/E ratio of -8.50 and a beta of 1.85.
In other news, Director Michael Raab sold 5,000 shares of the stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $11.16, for a total transaction of $55,800.00. Following the completion of the sale, the director now directly owns 13,895 shares in the company, valued at $155,068.20. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO John F. Crowley sold 20,000 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $11.15, for a total transaction of $223,000.00. Following the completion of the sale, the chief executive officer now owns 770,399 shares of the company’s stock, valued at $8,589,948.85. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 65,000 shares of company stock valued at $779,000. Corporate insiders own 2.50% of the company’s stock.
Large investors have recently bought and sold shares of the business. Sageworth Trust Co bought a new position in shares of Amicus Therapeutics in the first quarter valued at $34,000. Meeder Asset Management Inc. bought a new position in shares of Amicus Therapeutics during the second quarter valued at about $73,000. Strs Ohio lifted its position in shares of Amicus Therapeutics by 176.9% during the first quarter. Strs Ohio now owns 10,800 shares of the biopharmaceutical company’s stock valued at $146,000 after purchasing an additional 6,900 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Amicus Therapeutics during the first quarter valued at about $202,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Amicus Therapeutics by 53.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,161 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 5,595 shares in the last quarter.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.
Featured Story: Equal Weight Rating
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.